Mechanism of peripheral noradrenergic stimulation by clozapine

Neuropsychopharmacology

Volumn 20, Issue 1, 1999, Pages 29-34

  Elman, Igor ^a   Goldstein, David S ^a   Eisenhofer, Graeme ^a   Folio, Joan ^a   Malhotra, Anil K ^a   Adler, Caleb M ^a   Pickar, David ^a   Breier, Alan ^a  

^a NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

Author keywords

Catecholamine; Clozapine; Fluphenazine; Norepinephrine; Schizophrenia; Spillover

Indexed keywords

3,4 DIHYDROXYPHENYLETHYLENE GLYCOL; AMINE OXIDASE (FLAVIN CONTAINING); CATECHOL; CLOZAPINE; DIHYDROXYPHENYLACETIC ACID; FLUPHENAZINE; NORADRENALIN; PLACEBO;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFECT; FEMALE; HORMONE METABOLISM; HORMONE RELEASE; HUMAN; MALE; NORADRENERGIC SYSTEM; PRIORITY JOURNAL; SCHIZOPHRENIA;

ADULT; ANALYSIS OF VARIANCE; ANTIPSYCHOTIC AGENTS; CATECHOLS; CLOZAPINE; DIHYDROXYPHENYLALANINE; FEMALE; HUMANS; MALE; METABOLIC CLEARANCE RATE; MONOAMINE OXIDASE; NOREPINEPHRINE; SCHIZOPHRENIA; TIME FACTORS; TRITIUM;

EID: 0032943627     PISSN: 0893133X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0893-133X(98)00047-5     Document Type: Article

References (30)

1. Ackenheil M. Clozapine-pharmacokinetic investigations and biochemical effects in man. Psychopharmacology (Berl). 99:1989;S32-S37.
2. 3H-noradrenaline from the cerebral cortex. Life Sci. 23:1978;1775-1780.
3. Axelrod F.B., Goldstein D.S., Holmes C., Berlin D., Koplin I.J. Pattern of plasma levels of catecholamines in familial dysautonomia. Clin Auton Res. 6:1996;205-209.
4. Baldessarini R.J., Frankenburg F.R. Clozapine. A novel antipsychotic agent N Engl J Med. 324:1991;746-754.
5. Breier A. Clozapine and noradrenergic function. Support for a novel hypothesis for superior efficacy J Clin Psychiatr. 55:1994;122-125.
6. Breier A., Buchanan R.W., Kirkpatrick B., Davis O.R., Irish D., Summerfelt A., Carpenter W.T. Effects of clozapine on positive and negative symptoms in outpatients with schizophrenia. Am J Psychiatr. 151:1994;20-26. a.
7. Breier A., Buchanan R.W., Waltrip R.W., Listwak S., Holmes C., Goldstein D.S. The effect of clozapine on plasma norepinephrine. Relationship to clinical efficacy Neuropsychopharmacology. 10:1994;1-7. b.
8. Brown A.S., Gewirtz G., Harkavy-Friedman J., Cooper T., Brebion G., Amador X.F., Malaspina D., Gorman J. Effects of clozapine on plasma catecholamines and relationship treatment response in schizophrenia. A within-subject comparison with haloperidol Neuropsychopharmacology. 17:1997;317-325.
9. Davidson M., Kahn R.S., Stern R.G., Hirschowitz J., Apter S., Knott P., Davis K.L. Treatment with clozapine and its effect on plasma homovanillic acid and norepinephrine concentrations in schizophrenia. Psychiatr Res. 46:1993;151-163.
10. Eisenhofer G., Goldstein D.S., Stull R., Keiser H.R., Sunderland T., Murphy D.L., Kopin I.J. Simultaneous liquid-chromatographic determination of 3,4-dihydroxyphenylglycol, catecholamines, and 3,4-dihydroxyphenylalanine in plasma, and their responses to inhibition of monoamine oxidase. Clin Chem. 32:1986;2030-2033.
11. Eisenhofer G., Esler M.D., Meredith I.T., Ferrier C., Lambert G., Jennings G. Neuronal reuptake of noradrenaline by sympathetic nerves in humans. Clin Sci (Colch). 80:1991;257-263.
12. Eisenhofer G., Friberg P., Rundqvist B., Quyyumi A.A., Lambert G., Kaye D.M., Kopin I.J., Goldstein D.S., Esler M.D. Cardiac sympathetic nerve function in congestive heart failure. Circulation. 93:1996;1667-1676.
13. Esler M., Jackman G., Bobik A., Kelleher D., Jennings G., Leonard P., Skews H., Korner P. Determination of norepinephrine apparent release rate and clearance in humans. Life Sci. 25:1979;1461-1470.
14. Esler M., Jackman G., Leonard P., Skews H., Bobik A., Korner P. Effect of norepinephrine uptake blockers on norepinephrine kinetics. Clin Pharmacol Ther. 29:1981;12-20.
15. Esler M., Jennings G., Lambert G., Meredith I., Horne M., Eisenhofer G. Overflow of catecholamine neurotransmitters to the circulation. Source, fate, and functions Physiol Rev. 70:1990;963-985.
16. Goldstein D.S. Stress, Catecolamines, and Cardiovascular Disease. 1995;Oxford University Press, Oxford, UK.
17. Goldstein D.S., Eisenhofer G., Stull R., Folio C.J., Keiser H.R., Kopin I.J. Plasma dihydroxyphenylglycol and the intraneuronal disposition of norepinephrine in humans. J Clin Invest. 81:1988;213-220.
18. Goldstein D.S., Hahn S.H., Holmes C., Tifft C., Harvey-White J., Milstien S., Kaufman S. Monoaminergic effects of folinic acid, L-DOPA, and 5-hydroxytryptophan in dihydropteridine reductase deficiency. J Neurochem. 64:1995;2810-2813.
19. Green A.I., Alam M.Y., Sobieraj J.T., Pappalardo K.M., Waternaux C., Salzman C., Schatzberg A.F., Schildkraut J.J. Clozapine response and plasma catecholamines and their metabolites. Psychiatr Res. 46:1993;139-149.
20. Hovevey-Sion D., Eisenhofer G., Kopin I.J., Kirk K.L., Chang P.C., Szemeredi K., Goldstein D.S. Metabolic fate of injected radiolabelled dopamine and 2-fluorodopamine in rats. Neuropharmacology. 29:1990;881-887.
21. Iversen L.L. Catecholamine uptake processes. Br Med Bull. 29:1973;130-135.
22. Kaler S.G., Goldstein D.S., Holmes C., Salerno J.A., Gahl W.A. Plasma and cerebrospinal fluid neurochemical pattern in Menkes disease. Ann Neurol. 33:1993;171-175.
23. Kane J., Honigfeld G., Singer J., Meltzer H. Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch Gen Psychiatr. 45:1988;789-796.
24. Leiberman J., Johns C., Cooper T., Pollack S., Kane J. Clozapine pharmacology and tardive dyskinesia. Psychopharmacology (Berl). 99:1989;S54-S59.
25. Leiberman J., Johns C., Pollack S., Masiar S., Bookstein P., Cooper T., Iadorola M., Kane J. Biochemical effects of clozapine in cerebrospinal fluid of patients with schizophrenia. Advances in neuropsychiatry and psychopharmacology Schizophrenia Res. 1:1991;341-349.
26. Meltzer H.Y. Clozapine. Is another view valid? Am J Psychiatr. 152:1995;821-825.
27. Meltzer H.Y., Thompson P.A., Lee M.A., Ranjan R. Neuropsychologic deficits in schizophrenia. Relation to social function and effect of antipsychotic drug treatment Neuropsychopharmacology. 14:1996;27S-33S.
28. Pickar D., Owen R.R., Litman R.E., Konicki E., Gutierrez R., Rapaport M.H. Clinical and biologic response to clozapine in patients with schizophrenia. Cross-over comparison with fluphenazine. Arch Gen Psychiatr. 49:1992;345-353.
29. Richelson E., Nelson A. Antagonism by neuroleptics of neurotransmitter receptors of normal human brain in vitro. Eur J Pharmacol. 103:1984;197-204.
30. Souto M., Monti J.M., Altier H. Effects of clozapine on the activity of central dopaminergic and noradrenergic neurons. Pharmacol Biochem Behav. 10:1979;5-9.